LEP and acute myeloid leukemia: In the independent validation cohort (consisting of patients with AML only), multivariate Cox regression analysis revealed a significant increase of relapse risk with lower serum Leptin levels in patients of intermediate and advanced stage only (serum Leptin (pg/mL) × disease stage (intermediate/advanced)—HR (95% CI): 0.83 (0.72–0.96); p = 0.013; Table S4).